Orforglipron with insulin glargine: larger HbA1c fall than placebo in phase 3

The study

This is the results record on ClinicalTrials.gov (NCT06109311) for a phase 3, randomised, double-blind trial sponsored by Eli Lilly and Company. It compared once daily oral orforglipron with placebo. The record lists 546 participants.

Participants were adults with type 2 diabetes and inadequate glycaemic control on insulin glargine, with or without metformin and/or an SGLT-2 inhibitor. The study was planned to last about 46 weeks, with up to 20 visits. Orforglipron was tested at 3 mg, 12 mg and 36 mg.

The primary outcome was the change in HbA1c from baseline to week 40.

What they found

The list below shows least squares mean changes in HbA1c (unit: percentage of HbA1c). A negative value means HbA1c fell. The record gives a "spread" value for each arm but does not say what it measures.

• Placebo: fell, change -0.77 (spread 0.078)
• Orforglipron 3 mg: fell, change -1.54 (spread 0.097)
• Orforglipron 12 mg: fell, change -2.05 (spread 0.098)
• Orforglipron 36 mg: fell, change -1.90 (spread 0.111)

The record lists three mixed model analyses, each with p <0.001. The net differences (LS mean) are -0.77, -1.28 and -1.13. The record does not label which dose each line refers to. It also does not report confidence intervals.

The placebo group also had a fall in HbA1c. The comparison with placebo is therefore the key result, not the within-arm change.

How much weight to give it

The design is strong for the question asked. It is a phase 3, randomised, double-blind, placebo-controlled trial, so differences between arms can reasonably be linked to the treatment.

There are important limits:

• This is a registry results record, not a journal paper. Methods and context are brief.
• HbA1c is a surrogate outcome. The record reports no hard outcomes such as cardiovascular events or kidney outcomes.
• The record does not report safety, tolerability, hypoglycaemia, body weight, baseline HbA1c or discontinuation rates.
• The study was planned to last about 46 weeks. The record does not describe what happened between week 40 and the end of the study.
• The sponsor is Eli Lilly and Company. The record does not report other funding details.
• The record does not say how the three dose arms compare with each other.

For your clinic

These data suggest that orforglipron lowered HbA1c more than placebo at week 40 in adults on insulin glargine in this trial. This is not enough to guide individual prescribing decisions.

Before this informs practice, read the full publication and any regulatory or guideline documents. Look for safety and tolerability data, hypoglycaemia rates, weight effects and how the trial population compares with patients in your clinic. Until then, treat this as an efficacy signal on a surrogate outcome.